Signature is pursuing a number of potential collaborative opportunities including partnerships with pharmaceutical corporations to support clinical development of leading signal transduction drugs and thus to develop new prognostic and predictive signatures leading to innovative advances in the treatment of cancer. In addition, Signature is seeking collaborations with major hospitals and diagnostic biotech companies towards the identification and validation of molecular signatures for outcome prediction and drug response in major solid tumors.

The company also supports leading healthcare providers in Germany and Europe in developing new diagnostic strategies for patient stratification towards existing and patented oncology drugs. Our competitive advantage is a unique combination of different fields and technologies including molecular pathology, molecular oncology and molecular profiling supported by the most advanced Affymetrix array technologies for the discovery of predictive diagnostics.